Skip to content

Episealer® Knee

The only individualised implant for focal cartilage lesions in the knee

Learn more

Episealer® Talus

Personalised implant for osteochondral lesions in the ankle

Learn more

Episealer® Patellofemoral System

For patients with osteoarthritis of the patellofemoral joint

Learn more

The Episurf Process

To ensure you receive the best possible treatment for your cartilage lesion, every step in the process focuses on you.

MRI Scan
To obtain a clear image of the lesion and your knee, 2D and 3D MRI scans are taken
Damage Marking Report
These images are then used to create a virtual 3D model and visualisation of your knee joint
Episealer
This 3D model is the basis for the design of your individualised Episealer implant

Episealer Products

Patient testimonials

Press releases and financial reports

Episurf Medical has entered into an amendment agreement regarding the acquisition of Kuststaden Invest

Episurf Medical AB (publ) (Nasdaq: EPIS B) (“Episurf”) has entered into an amendment agreement to the share purchase agreement regarding the acquisition of all shares in Kuststaden Invest AB (“Kuststaden”), which was announced on 10 June 2026. Under the amendment agreement, the issue price for the consideration shares is reduced from SEK 0.10 to SEK 0.075 per B share. The cash portion of the purchase price of SEK 70 mn will be paid on the closing date by…

    Conversion of convertibles in a nominal amount of SEK 87,509,176 to 1,591,075,927 Class B shares

    On 4 June 2026, Episurf Medical AB (publ) (“Episurf“) issued convertibles in an aggregated nominal amount of SEK 87,509,176 as part of the consideration to be paid for the acquisition of a property portfolio from Mofast AB. Convertibles in a nominal amount of SEK 87,509,176 have, as of the date of this press release, at the request from holders of convertibles, been converted into 1,591,075,927 Class B shares in Episurf at a conversion price of…

    The Board of Directors of Episurf withdraws the proposal for a resolution on the approval of a transaction between a subsidiary and a related party

    Episurf Medical AB (“Episurf” or the “Company“) announces that the Board of Directors has resolved to withdraw the proposal for a resolution on the approval of a related-party transaction between a subsidiary and a related party from the agenda of the Extraordinary General Meeting to be held on Thursday, 12 November 2026. The Board of Directors’ proposal for a resolution at the Extraordinary General Meeting concerned the approval of Episurf’s subsidiary Frusipe Intressenter Target 1…